Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors Refractory To Standard Therapy”

Showing 4 of 0 results

Early research (Phase 1)Study completedNCT00949949
What this trial is testing

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Who this might be right for
Cholangiocarcinoma of the GallbladderLocalized Gallbladder CancerUnresectable Gallbladder Cancer+1 more
Mayo Clinic 38
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Early research (Phase 1)Study completedNCT02499224
What this trial is testing

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Who this might be right for
Solid Tumors
CellabMED 39
Early research (Phase 1)Study completedNCT04686383
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Who this might be right for
Resistant or Refractory Solid Tumors
Calgent Biotechnology Co., Ltd 17

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation